Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Cancer Gene Ther. 2012 May 4;19(6):431–442. doi: 10.1038/cgt.2012.21

Figure 2.

Figure 2

Adenoviral progeny released from infected HB1.F3-CD effectively lyses glioma cell lines. (a) The supernatant and cells, infected with 50 i.u./cell of CRAd-S-pk7, were collected and analyzed separately. The viral progeny inside the cells (cell associated) and the progeny released by the infected cells (released virus) over time were measured by the titer assay. The supernatant of HB1.F3-CD cells infected with different concentrations of CRAd-S-pk7 (0, 1, 10, 50 and 100 i.u./cell) was collected 5 days post-infection and used to infect different glioma cell lines (U87, U251, U118 and N10) and a lung adenocarcinoma cell line (A549). Viability was assessed 3 days later via crystal violet staining (b) and MTT viability assay (c). Error bars represent SEM; *, P-value <0.05.